Compare Gilead Sciences, Inc. (GILD) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Transocean Ltd — how do they compare? Gilead Sciences, Inc. trades at $134.5 (market cap $163.51B), while Transocean Ltd trades at $5.14 (market cap $5.76B). The key difference: Gilead Sciences, Inc. is far larger — about 28.4× Transocean Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| GILD | RIG | |
|---|---|---|
Market Cap | $163.51B | $5.76B |
Sector | Health | Technology |
52-Week High | $155.80 | $7.58 |
52-Week Low | $108.22 | $2.55 |
Enterprise Value | $178.05B | $10.70B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Transocean Ltd. (RIG) trades at $5.165, down 2.73% on the day, reflecting ongoing investor concerns about persistent net losses despite strong revenue growth. The stock shows bearish technical signals with mixed fundamental indicators: a low P/B ratio of 0.7 suggests undervaluation, but negative ROE (-30.05%) and net income margins (-66.79%) highlight profitability challenges. Recent business developments include securing over $1 billion in new contracts with Equinor and progressing a major merger with Valaris Limited, which could transform the company's competitive position.
The investment outlook balances significant operational momentum against substantial financial risks. The expanding contract backlog and pending Valaris merger offer potential for improved scale and synergies, while high debt levels and consistent net losses present clear challenges to shareholder value creation. Analyst consensus remains cautiously optimistic with a $7.00 price target, but the stock's direction will likely depend on execution of the merger and path to sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
